Genmab — April 2016
-
Jeg prøver mit spørgsmål fra før igen: Hvornår kan vi vente nyheder omkring tisotumab vedotin? Årsagen til jeg spørger er, at jeg tror det er en meget vigtig trigger, fordi der ikke på forhånd er næsten givet at det er succesfuldt. Og det vil medføre opt in fra SGEL, som ikke allerede er indregnet?
-
Tak Viborg76
-
Jeg mener dette er vigtigt, fordi GEN kommer længere frem i solide tumorer. Samtidig har analytikere ikke indregnet næsten 100% sandsynlighed for succes som med Castor og Pollux. Derved mener jeg at hvis der vises gode data, så kan der komme en meget fin kursstigning
-
Tak Bulder. Det vil jeg glæde mig til
-
den har ikke opdateret i lang tid
-
Fra blogbuster: The CHMP met today and has given Darzalex the green light: Dara wins EMA backing for approval. It shouldn’t be long now before official EMA registration. A great way to close an awesome week… Today, the Committee has issued a positive opinion recommending the grant of a conditional marketing authorisation for Darzalex in the EU for treatment of relapsed and refractory multiple myeloma. Darzalex has an orphan designation and was reviewed under EMA’s accelerated assessment scheme.
-
On September 9, Janssen filed with the EMA and today, 205 days later, the positive opinion was issued. That’s close to their 210 day regular schedule, however, with its very rare ‘accelerated assessment‘ the EMA skips the 3-months clock stop. As such, this opinion has come 3 months and 5 days faster.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind